There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
deaths globally due, in part, to the majority of patients being diagnosed with intermediate or …

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates
are constantly increasing. Despite the availability of potentially curative treatments (liver …

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …